WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company
that is a leader in the development of sustained release ophthalmic drug
treatments, today announced that the Company's Vice President of
Research, Dr. Hong Guo, will present a paper at the 5thOcular Diseases and Drug Development Conference in San Francisco on
March 21. Dr. Guo's presentation will take place at 10:30 a.m.
Dr. Guo's presentation entitled "Sustained delivery of proteins and
anti-bodies" is expected to discuss recent developments in pSivida's
Tethadur technology.
"One of the many challenges to the pharmaceutical industry is to develop
effective delivery systems for protein and antibody drugs," said Dr.
Paul Ashton, President and CEO of pSivida. "Dr. Guo will describe
results we have had with our proprietary Tethadur system, which is based
on bioerodible, nanostructured, porous silicon. With the large number of
biologic patents expiring and the development of the Bio-similar field,
improved protein delivery will become increasingly important."
pSivida has previously announced a technology evaluation agreement with
a leading global biopharmaceutical company investigating the use of this
technology in ophthalmology.
The Ocular Diseases and Drug Development Conference promotes the
discovery of ocular disease development by bringing together leading
scientists, researchers and experts to discuss and collaborate on the
latest research and development, safety assessment, regulatory issues
and drugs in development for combating and curing age-related macular
degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and
other ocular diseases. Among those participating are representatives
from most of the pharmaceutical companies that are involved in the
development of treatments for these conditions.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drugs delivery products designed to release drugs at a
controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye
utilizing its core technology systems, Durasert™ and BioSilicon™. Two
FDA-approved products, Vitrasert™ and Retisert™ are licensed to Bausch &
Lomb. The company has licensed ILUVIEN® for DME to Alimera Sciences and
that product has received marketing authorization in Austria, France,
Germany, Portugal, Spain and the UK. pSivida has clinical trials ongoing
for the treatment of posterior uveitis and glaucoma and ocular
hypertension. Other technologies under development by pSivida include
protein and antibody delivery systems in early clinical stages.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. The following are
some of the factors that could cause actual results to differ materially
from the anticipated results or other expectations expressed,
anticipated or implied in our forward-looking statements: uncertainties
with respect to: Alimera's ability to finance, achieve additional
marketing approvals, successfully commercialize and achieve market
acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in
the EU; outcome of reimbursement for ILUVIEN in the U.K., Alimera's
resubmission of its NDA for ILUVIEN for DME and its ability to obtain
regulatory approval for, and if approved, to finance, successfully
commercialize and achieve market acceptance of, and generate revenues to
pSivida from, ILUVIEN for DME in the U.S.; financing and success of
Phase III posterior uveitis trials including efficacy, side effects and
risk/benefit profile of the posterior uveitis micro-insert; initiation,
financing and success of Latanoprost Product Phase II trials and
exercise by Pfizer of its option; development of products using Tethadur
and BioSilicon; initiation and completion of clinical trials and
obtaining regulatory approval of product candidates; adverse side
effects; ability to attain profitability; ability to obtain additional
capital; further impairment of intangible assets; fluctuations in
operating results; decline in royalty revenues; ability to, and to find
partners to, develop and market products; termination of license
agreements; competition and other developments affecting sales of
products; market acceptance; protection of intellectual property and
avoiding intellectual property infringement; retention of key personnel;
product liability; consolidation in the pharmaceutical and biotechnology
industries; compliance with environmental laws; manufacturing risks;
risks and costs of international business operations; credit and
financial market conditions; legislative or regulatory changes;
volatility of stock price; possible dilution; possible influence by
Pfizer; absence of dividends; and other factors described in our filings
with the SEC. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. Our
forward-looking statements speak only as of the dates on which they are
made. We do not undertake any obligation to publicly update or revise
our forward-looking statements even if experience or future changes
makes it clear that any projected results expressed or implied in such
statements will not be realized.
In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak,
President
312-943-1123; 773-350-5793 (cell)
bjedynak@janispr.com
or
In
Australia:
pSivida Corp.
Brian Leedman, Vice President,
Investor Relations
+61 (0) 41 228 1780
brianl@psivida.com
Source: pSivida Corp.
News Provided by Acquire Media
